Autolus Therapeutics Changes Auditor from EY UK to EY US, Citing No Disagreements

summarizeSummary

Autolus Therapeutics changed its independent auditor from EY UK to EY US, a move within the same global firm, with no reported disagreements but a reminder of prior material weaknesses in internal controls.

check_boxKey Events

• Auditor Dismissal

  Autolus Therapeutics dismissed Ernst & Young LLP (UK) as its independent registered public accounting firm on April 14, 2026.

• New Auditor Appointment

  The Audit Committee approved the engagement of Ernst & Young LLP (US) as the new independent registered public accounting firm, effective immediately for the fiscal year ending December 31, 2026.

• No Accounting Disagreements

  The company reported no disagreements with EY UK on accounting principles or practices that would have impacted their audit reports for the past two fiscal years.

• Prior Material Weakness Noted

  The filing referenced a previously disclosed material weakness in internal controls over financial reporting as of March 31, 2024, which was initially reported in a Form 10-Q.

auto_awesomeAnalysis

Autolus Therapeutics dismissed Ernst & Young LLP (UK) and appointed Ernst & Young LLP (US) as its new independent registered public accounting firm. While the change is within the same global firm and no disagreements on accounting principles or practices were reported, the filing reminds investors of previously disclosed material weaknesses in internal controls as of March 31, 2024. This transition, though not indicative of a dispute, warrants attention as the company navigates its financial health and product launches.